Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Zolinza Generic Name & Formulations
Legal Class
Rx
General Description
Vorinostat 100mg; caps.
Pharmacological Class
Histone deacetylase inhibitor.
How Supplied
Caps—120
Manufacturer
Zolinza Indications
Indications
Refractory cutaneous T-cell lymphoma.
Zolinza Dosage and Administration
Adult
Take with food. Swallow whole. 400mg once daily. If not tolerated, may reduce to 300mg once daily, then to 300mg once daily 5 days/week if needed. Continue until disease progression or not tolerated.
Children
<18yrs: not established.
Zolinza Contraindications
Not Applicable
Zolinza Boxed Warnings
Not Applicable
Zolinza Warnings/Precautions
Warnings/Precautions
Prior history of thromboembolism; monitor for DVT, PE. Correct electrolyte disturbances before starting therapy. Maintain adequate hydration. Diabetes. Monitor CBC, platelets, blood glucose, serum creatinine, electrolytes (esp. potassium, calcium, magnesium) every 2 weeks for 1st 2 months, then monthly. Hepatic impairment. Embryo-fetal toxicity. Pregnancy: exclude status within 7 days prior to initiation. Use effective contraception during and for ≥6months (females) or ≥3months (males w. female partners) after the last dose. Nursing mothers: not recommended (during and for ≥1week after the last dose).
Zolinza Pharmacokinetics
See Literature
Zolinza Interactions
Interactions
Increased risk of thrombocytopenia and GI bleed with other HDAC inhibitors (eg, valproic acid); monitor. Concomitant warfarin: monitor PT, INR frequently.
Zolinza Adverse Reactions
Adverse Reactions
GI symptoms (eg, diarrhea, nausea, anorexia, weight decrease, vomiting, constipation), fatigue, chills, thrombocytopenia, anemia (may need to modify dose or discontinue), dysgeusia, dry mouth; PE, DVT, hyperglycemia.
Zolinza Clinical Trials
See Literature
Zolinza Note
Not Applicable
Zolinza Patient Counseling
See Literature
